We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Corgentech and Bristol-Myers Squibb (BMS) have announced top-line results from
PREVENT IV, a Phase III clinical trial evaluating the use of edifoligide (E2F
Decoy), an investigational product, to prevent vein graft failure following
coronary artery bypass graft (CABG) surgery.
Adventrx Pharmaceuticals has received a final advice letter from the European
Medicines Agency (EMEA) for its proposed CoFactor trial protocol in pancreatic
cancer.
Discovery Partners International (DPI) and Chroma Therapeutics have entered
into a collaboration focused on the discovery of potential new lead compounds
against several selected targets.
Swiss Medica has announced positive results of the randomized, double-blind,
clinical trial comparing the company's O24 pain reliever against a placebo on
patients suffering from fibromyalgia.
Vion Pharmaceuticals has commenced dosing the first patient on the Phase III
pivotal trial of its anticancer agent Cloretazine (VNP40101M) in relapsed acute
myelogenous leukemia.
Advancis Pharmaceutical has enrolled 504 adult/adolescent patients in the company's
Amoxicillin PULSYS Phase III clinical trial for the treatment of pharyngitis/tonsillitis
from Group A streptococcal infections.